The values of the atherogenicity
index (AI), thrombogenicity index (TI) and theratio between hypocholesterolemic and hypercholesterolemic fatty acids (H/H) are shown in Table 3.
Grape powder polyphenols attenuate atherosclerosis development in apolipoprotein E deficient (E0) mice and reduce macrophage atherogenicity
It was demonstrated that blood serum atherogenicity
decreased in study subjects treated with a single dose of hawthorn extract.
Table 1 shows the atherogenicity
and thrombogenicity indexes which are associated with the presence of lauric (12:0), myristic (14:0), palmitic (16:0) and stearic (18:0) fatty acids, and the increased incidence of coronary diseases when compared to monounsaturated fatty acids, especially oleic (18:1 n-9) and the series omega 3 and 6.
In an individual without the MetS, atherogenicity
of the elevated and dysfunctional apoA-I would be independent of Lp(a) and other established factors, as current findings suggested.
of blood serum from patients with coronary heart disease.
Although the overall effects of the n-3 FAs on serum lipoproteins appear to be beneficial, particularly with respect to VLDL, their susceptibility to oxidation due to their high unsaturation may induce peroxidative damage to LDL, thus increasing the atherogenicity
of the lipoprotein fraction .
Research on insulin and fat metabolism over the past several decades has shown that the carbohydrate hypothesis is correct, and that instead of fat and cholesterol causing heart disease, it is the carbohydrates that determine the atherogenicity
Defining the atherogenicity
of large and small lipoproteins containing apolipoprotein B-100.
of lipoprotein particles is determined by particle concentration as well as other variables, including particle size, lipid composition, and distinct surface apolipoproteins.
2003) Antioxidative probiotic fermented goats' milk decreases oxidative stress mediated atherogenicity
in human subjects.
When blood serum samples from the Allicor patients were added to a culture of human aortic cells, a reduction in laboratory indicators of atherogenicity
was seen over a 12-hour period, compared with samples from placebo patients.